"Because the healthcare systems in different countries vary considerably, we shouldn't automatically assume that a new drug that gives good value for money in one country will do so an another," states Professor Michael Drummond, co-author of the study. Study results emphasized the fact that economic evaluations in one country give little basis on which to predict cost-effectiveness across borders.
Factors affecting the variations include demography and epidemiology of disease, difference in clinical practice patterns, and differences in relative prices cross-country. This variability is a particular concern for decision makers, those conducting economic studies and particularly pharmaceutical manufacturers, who may have to consider repeating studies in every possible setting.
This study is published in Value in Health.
About Value in Health
Value in Health is a multidisciplinary peer-reviewed journal reporting on evaluations of medical technologies including pharmaceuticals, biologics, devices, procedures, and other health care interventions. As the official journal of the International Society for Pharmacoeconomics and Outcomes Research, the Journal provides a scientific forum for communicating health economics and outcomes research methods and findings.
About Blackwell Publishing
Blackwell Publishing is the world's leading society publisher, partnering with more than 600 academic and professional societies. Blackwell publishes over 750 journals and 600 text and reference books annually, across a wide range of academic, medical, and professional subjects.
The above story is based on materials provided by John Wiley & Sons, Inc.. Note: Materials may be edited for content and length.
Cite This Page: